Iron and Parkinson's disease: Chelators to the rescue?

Nutrition Reviews

Volumn 61, Issue 9, 2003, Pages 311-313

  Levenson, Cathy W ^a  

^a FLORIDA STATE UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Chelation; Dopamine; Iron; Oxidation; Parkinson's disease

Indexed keywords

CHELATING AGENT; CLIOQUINOL; CYANOCOBALAMIN; DOPAMINE; IRON;

ANEMIA; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; HUMAN; IRON CHELATION; IRON INTAKE; MOTOR DYSFUNCTION; NERVE CELL LESION; NEUROPATHOLOGY; NONHUMAN; OXIDATION; PARKINSON DISEASE; PATHOGENESIS; SHORT SURVEY; SIDE EFFECT;

HUMANS; IRON; IRON CHELATING AGENTS; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 0141992786     PISSN: 00296643     EISSN: None     Source Type: Journal    
DOI: 10.1301/nr.2003.sept.311-313     Document Type: Short Survey

References (18)

1. Connor JR, Snyder BS, Beard JL, Fine RE, Mufson EJ. Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer's disease. J Neurosci Res. 1992;31:327-335.
2. Koeppen AH, Dickson AC. Iron in the Hallervorden-Spatz syndrome. Pediatr Neurol. 2001;25:148-155.
3. Bartzokis G, Cummings J, Perlman S, Hance DB, Mintz J. Increased basal ganglia iron levels in Huntington disease. Arch Neurol. 1999;56:569-574.
4. Dexter DT, Wells FR, Lees AJ, et al. Increased nigral iron content in postmortem parkinsonian brain. Lancet. 1987;21:1219-1220.
5. Sofic E, Riederer P, Heinsen H, et al. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm. 1988;74:199-205.
6. Gorell JM, Ordidge RJ, Brown GG, Deniau JC, Buderer NM, Helpern JA. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology. 1995;45:1138-1143.
7. Berg D, Becker G, Zeiler B, et al. Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology. 1999;53:1026-1031.
8. Qian ZM, Wang Q. Expression of iron transport proteins and excessive iron accumulation in the brain in neurodegenerative disorders. Brain Res Rev. 1998;27:257-267.
9. Berg D, Gerlach M, Youdim MBH, et al. Brain iron pathways and their relevance to Parkinson's disease. J Neurochem. 2001;79:225-236.
10. Riederer P, Sofic WD, Rausch B, et al. Transition metal, ferritin, glutathione, and ascorbic acid in parkinsonian brain. J Neurochem. 1989;52:515-520.
11. Uversky VN, Li J, Fink AL. Metal-triggered structural transformations, aggregation, and fibrillation of human α-synuclein. A possible molecular link between Parkinson's disease and heavy metal exposure. J Biol Chem. 2001;47:44284-44296.
12. Kaur D, Yanitiri F, Subramanian R, et al. Genetic or pharmacological iron chelation prevent MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron. 2003;37:899-909.
13. Cheepsunthorn P, Palmer C, Connor JR. Cellular distribution of ferritin subunits in postnatal rat brain. J Comp Neurol. 1998;400:73-86.
14. Connor JR, Menzies SL Cellular management of iron in the brain. J Neurol Sci. 1995;134:33-44.
15. Yassin MS, Ekblom J, Xilinas M, Gottfries CG, Oreland L. Changes in uptake of vitamin B(12) and trace metals in brain of mice treated with clioquinol. J Neurol Sci. 2000;173:40-44.
16. Cherny RA, Atwood CS, Xilinas ME, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron. 2001;30:665-676.
17. Masters C. Alzheimer's disease: modulation of the APP/beta-amyloid pathways toward rational therapeutic intervention. 8th International Conference on Alzheimer's Disease and Related Disorders; 2002.
18. Atwood CS, Scarpa RC, Huang X, et al. Characterization of copper interactions with alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta1-42. J Neurochem. 2000;75:1219-1233.